XML 52 R15.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Geographic and Product Data | 9 Months Ended
--- | ---
Sep. 29, 2017
Segment Reporting [Abstract] |
Segment Reporting Disclosure [Text Block] | Note 9 — Geographic and Product Data The Company markets and sells its products in over 60 countries and conducts its manufacturing in the United States. Other than China, Japan, and the United States, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated sales. Sales are generally attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers is set forth below (in thousands):
|  | Three Months Ended |  | Nine Months Ended |
|  | September 29, |  | September 30, |  | September 29, |  | September 30, |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |
China |  | $ | 7,164 |  | $ | 4,254 |  | $ | 17,489 |  | $ | 11,749 |
Japan |  |  | 4,633 |  |  | 4,029 |  |  | 12,849 |  |  | 12,258 |
United States |  |  | 1,896 |  |  | 2,419 |  |  | 5,946 |  |  | 7,355 |
Other |  |  | 9,780 |  |  | 9,350 |  |  | 29,475 |  |  | 28,933 |
Total |  | $ | 23,473 |  | $ | 20,052 |  | $ | 65,759 |  | $ | 60,295 |
100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery. The composition of the Company’s net sales by product line is as follows (in thousands):
|  | Three Months Ended |  | Nine Months Ended |
|  | September 29, |  | September 30, |  | September 29, |  | September 30, |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |
ICLs |  | $ | 18,110 |  | $ | 14,801 |  | $ | 49,698 |  | $ | 43,389 |
IOLs |  |  | 3,892 |  |  | 4,649 |  |  | 12,875 |  |  | 14,783 |
Other surgical products |  |  | 1,471 |  |  | 602 |  |  | 3,186 |  |  | 2,123 |
Total |  | $ | 23,473 |  | $ | 20,052 |  | $ | 65,759 |  | $ | 60,295 |
One customer, our distributor in China, accounted for 31% and 27% of net sales for the three and nine months ended September 29, 2017, respectively, and the same customer accounted for 21% and 19% of net sales for the three and nine months ended September 30, 2016, respectively. As of September 29, 2017 and December 30, 2016, respectively, one customer, our distributor in China, accounted for 26% and 22% of consolidated trade receivables.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration